2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
David F. McDermott, MD, Beth Israel Deaconess Medical Center, discusses the recent IMmotion150 trial in Renal Cell Carcinoma (RCC).
David F. McDermott, MD, Beth Israel Deaconess Medical Center, discusses the recent IMmotion150 trial in Renal Cell Carcinoma (RCC).
IMmotion150, a phase II, open-label, randomized study of atezolizumab (Tecentriq) in combination with bevacizumab (Avastin) versus sunitinib (Sutent) in patients with untreated advanced RCC, is the first large look at PD-L1 blockade with atezolizumab in patients with untreated advanced RCC, according to McDermott.
This trial address the question of whether adding VEGF blockade with bevacizumab to PD-L1 blockade with atezolizumab extends benefit. The answer seems to be, “Yes,” says McDermott, as survival outcomes did improve, particularly in the subset of patients with inflamed tumors.
Related Content: